Time to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe Psoriasis.

MLA

Kim PAPP, et al. “Time to Loss of Response Following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe Psoriasis.” Acta Dermato-Venereologica, vol. 102, Jan. 2022, pp. 1–4. EBSCOhost, https://doi.org/10.2340/actadv.v102.1984.

APA

Kim PAPP, Paul, C., Kleyn, C. E., Yu-Huei HUANG, Tsen-Fang TSAI, Schuster, C., El Baou, C., Toth, A., Riedl, E., & Mrowietz, U. (2022). Time to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe Psoriasis. Acta Dermato-Venereologica, 102, 1–4. https://doi.org/10.2340/actadv.v102.1984

Chicago

Kim PAPP, Carle Paul, C. Elise Kleyn, Yu-Huei HUANG, Tsen-Fang TSAI, Christopher Schuster, Celine El Baou, Agoston Toth, Elisabeth Riedl, and Ulrich Mrowietz. 2022. “Time to Loss of Response Following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe Psoriasis.” Acta Dermato-Venereologica 102 (January): 1–4. doi:10.2340/actadv.v102.1984.